Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure

This study sought to determine whether the sodium/glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved heart failure (HF) outcomes in nondiabetic mice. The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial demonstrated that em...

Descripción completa

Detalles Bibliográficos
Autores principales: Byrne, Nikole J., Parajuli, Nirmal, Levasseur, Jody L., Boisvenue, Jamie, Beker, Donna L., Masson, Grant, Fedak, Paul W.M., Verma, Subodh, Dyck, Jason R.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
LEADING EDGE IN TRANSLATIONAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034464/
https://www.ncbi.nlm.nih.gov/pubmed/30062155
http://dx.doi.org/10.1016/j.jacbts.2017.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034464/
https://www.ncbi.nlm.nih.gov/pubmed/30062155
http://dx.doi.org/10.1016/j.jacbts.2017.07.003

Ejemplares similares